Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution

Neuraminidase inhibitors (NAIs) are the only available licensed therapeutics against human H7N9 influenza virus infections. The emergence of NAI-resistant variants of H7N9viruses with an NA R292K mutation poses a therapeutic challenge. A comprehensive understanding of the susceptibility of these vir...

Full description

Bibliographic Details
Published in:	Emerging Microbes and Infections
Main Authors:	Xiaonan Zhang, Zhigang Song, Jing He, Hui-Ling Yen, Jianhua Li, Zhaoqin Zhu, Di Tian, Wei Wang, Lei Xu, Wencai Guan, Yi Liu, Sen Wang, Bisheng Shi, Wanju Zhang, Boyin Qin, Jialin Cai, Yanmin Wan, Chunhua Xu, Xiaonan Ren, Haili Chen, Lu Liu, Yuqin Yang, Xiaohui Zhou, Wenjiang Zhou, Jianqing Xu, Xiaoyan Zhang, Malik Peiris, Yunwen Hu, Zhenghong Yuan
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2014-01-01
Subjects:	H7N9 influenza virus neuraminidase oseltamivir peramivir
Online Access:	https://www.tandfonline.com/doi/10.1038/emi.2014.80

Similar Items

In Vitro Characterization of Multidrug-Resistant Influenza A(H1N1)pdm09 Viruses Carrying a Dual Neuraminidase Mutation Isolated from Immunocompromised Patients
by: Emi Takashita, et al.
Published: (2020-09-01)

A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment
by: Jui-Yi Chen, et al.
Published: (2020-02-01)

Efficacy and safety of intravenous peramivir versus oral oseltamivir in the treatment of influenza in children: A meta-analysis
by: Jie Yuan, et al.
Published: (2024-06-01)

An outbreak of influenza A(H1N1)pdm09 antigenic variants exhibiting cross-resistance to oseltamivir and peramivir in an elementary school in Japan, September 2024
by: Hideki Hasegawa
Published: (2024-12-01)

Impact of the R292K Mutation on Influenza A (H7N9) Virus Resistance towards Peramivir: A Molecular Dynamics Perspective
by: Sphamandla E. Mtambo, et al.
Published: (2022-03-01)

Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus
by: Shiang-Fen Huang, et al.
Published: (2017-10-01)

Comparative effectiveness of oseltamivir versus peramivir for hospitalized children (aged 0-5 years) with influenza infection
by: Ming Xu, et al.
Published: (2023-03-01)

Intermolecular Mechanism and Dynamic Investigation of Avian Influenza H7N9 Virus’ Susceptibility to E119V-Substituted Peramivir–Neuraminidase Complex
by: Sphamandla E. Mtambo, et al.
Published: (2022-03-01)

Peramivir: A novel intravenous neuraminidase inhibitor for treatment of acute influenza infections
by: Malak eAlame, et al.
Published: (2016-03-01)

Clinical and pharmacological approaches to present-day influenza anti-viral therapy
by: N. B. Lazareva, et al.
Published: (2018-04-01)

Mutations I117V and I117M and Oseltamivir Sensitivity of Pandemic (H1N1) 2009 Viruses
by: Aeron C. Hurt, et al.
Published: (2012-01-01)

Viral genome and antiviral drug sensitivity analysis of two patients from a family cluster caused by the influenza A(H7N9) virus in Zhejiang, China, 2013
by: Hai Nv Gao, et al.
Published: (2014-12-01)

Preparation and Evaluation of Oseltamivir Molecularly Imprinted Polymer Silica Gel as Liquid Chromatography Stationary Phase
by: Ya-Jun Yang, et al.
Published: (2018-07-01)

A critical analytical aspect on analytical protocols in the pharmaceutical analysis of H1N1 antiviral agent and its active metabolite
by: Suraj R. Chaudhari, et al.
Published: (2024-08-01)

Influenza: state of knowledge, treatment and prevention
by: Anna Majewska, et al.
Published: (2021-07-01)

Influenza in the COVID-19 era: principles of modern pharmacotherapy
by: N. B. Lazareva
Published: (2021-10-01)

Neuraminidase Inhibitors in Influenza Treatment and Prevention–Is It Time to Call It a Day?
by: César Parra-Rojas, et al.
Published: (2018-08-01)

Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH<sub>2</sub>-Acyl Oseltamivir Analogues as Potent Neuraminidase Inhibitors
by: Jiqing Ye, et al.
Published: (2021-04-01)

Interferon Lambda Delays the Emergence of Influenza Virus Resistance to Oseltamivir
by: Chiara Medaglia, et al.
Published: (2021-06-01)

Multicountry Spread of Influenza A(H1N1)pdm09 Viruses with Reduced Oseltamivir Inhibition, May 2023–February 2024
by: Mira C. Patel, et al.
Published: (2024-07-01)

Assessment of influenza A (H1N1, H3N2) oseltamivir resistance during 2017-2019 in Iran
by: Amytis Gholami, et al.
Published: (2022-08-01)

Etiotropic therapy and chemoprophylaxis of influenza with neuraminidase inhibitors
by: T. G. Zubkova, et al.
Published: (2020-01-01)

A novel N-heterocycles substituted oseltamivir derivatives as potent inhibitors of influenza virus neuraminidase: discovery, synthesis and biological evaluation
by: Jiwei Zhang, et al.
Published: (2023-12-01)

Discovery of Novel Boron-Containing <em>N</em>-Substituted Oseltamivir Derivatives as Anti-Influenza A Virus Agents for Overcoming N1-H274Y Oseltamivir-Resistant
by: Ruifang Jia, et al.
Published: (2022-09-01)

Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report
by: Naonori Harada, et al.
Published: (2020-07-01)

Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, Mexico
by: José Ernesto Ramirez-Gonzalez, et al.
Published: (2011-02-01)

Kinetic, Thermodynamic, and Structural Analysis of Drug Resistance Mutations in Neuraminidase from the 2009 Pandemic Influenza Virus
by: Jana Pokorná, et al.
Published: (2018-06-01)

Poor responses to oseltamivir treatment in a patient with influenza A (H7N9) virus infection
by: Xuhui Liu, et al.
Published: (2013-01-01)

Structural Investigations and Binding Mechanisms of Oseltamivir Drug Resistance Conferred by the E119V Mutation in Influenza H7N9 Virus
by: Samuel C. Ugbaja, et al.
Published: (2022-07-01)

Combination Chemotherapy for Influenza
by: Robert G. Webster, et al.
Published: (2010-07-01)

The Synthetic-Technical Development of Oseltamivir Phosphate Tamiflu™: A Race against Time
by: Stefan Abrecht, et al.
Published: (2007-03-01)

Different Inhibitory Potencies of Oseltamivir Carboxylate, Zanamivir, and Several Tannins on Bacterial and Viral Neuraminidases as Assessed in a Cell-Free Fluorescence-Based Enzyme Inhibition Assay
by: Stefanie Quosdorf, et al.
Published: (2017-11-01)

Oseltamivir-resistant influenza in a fatal immunocompromised adult
by: Hao-En Jan, et al.
Published: (2025-08-01)

Low prevalence of influenza A strains with resistance markers in Brazil during 2017–2019 seasons
by: Thiago das Chagas Sousa, et al.
Published: (2022-09-01)

Effectiveness of Antiviral Treatment with Intravenous Peramivir and Oral Oseltamivir for Seasonal Influenza in Children
by: Young-hoon Byun, et al.
Published: (2024-12-01)

Neuraminidase as a novel therapeutic management strategy for Alzheimer’s disease: evidenced through molecular docking, molecular dynamic simulation and gene expression analysis
by: Sami I. Alzarea, et al.
Published: (2025-05-01)

Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017
by: Toledo-Rueda W, et al.
Published: (2018-10-01)

Reduced Sensitivity of Influenza A (H5N1) to Oseltamivir
by: Jennifer L. McKimm-Breschkin, et al.
Published: (2007-09-01)

In Vitro and In Vivo Assessment of Pharmacokinetic Profile of Peramivir in the Context of Inhalation Therapy
by: Liuhan Dong, et al.
Published: (2025-01-01)

OSELTAMIVIR AS ANTIVIRAL THERAPY OF INFLUENZA A(H1N1)pdm09 IN CHILDREN AND ADULTS
by: L. V. Osidak, et al.
Published: (2016-09-01)